Predicted non-responders were randomly assigned ( 2:1 ) to receive four cycles of docetaxel ( 100 mg/m ( 2 ) intravenously every 3 weeks ) and trastuzumab ( 6 mg/kg intravenously every 3 weeks ) plus bevacizumab ( 15 mg/kg intravenously every 3 weeks ; group A ) or continue on docetaxel plus trastuzumab alone ( group B ) .